Analysts have clear opinions on AKBA.

There are 5 analysts on the Wall offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $13.80 with a high forecast of $16.00 and a low forecast of $8.00. The average price target represents a 149.55% increase from the last price of $5.53.
Akebia Therapeutics, Inc. (AKBA) is followed by 5 analysts on the street.

null from rates it a .

Similarly, null of a with a target of .

The consensus on the street is null.

What does Akebia Therapeutics, Inc.(AKBA) do ?
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Akebia Therapeutics, Inc. (AKBA) Insider Trades

Multiple company employees have indulged in significant insider trading. Akebia Therapeutics, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

SVP, COO, Dahan Michel : S – Sale+OE(-$60,656) of AKBA in the trading session of 2020-02-28.

SVP, GC Hadas Nicole R. : S – Sale+OE(-$61,335) of AKBA in the trading session of 2020-02-28.

SVP, CFO, Treasurer Amello Jason : S – Sale+OE(-$60,691) of Akebia Therapeutics, Inc. in the trading session of 2020-02-28.

Looking for stocks just like AKBA?

Based on Wall Street analyst research, several stocks are similar to AKBA
They are:
– FGEN [Info can be found here: ]
– JNJ [Info can be found here: ]
– ARDX [Info can be found here: ]